Article Details

Arcus Preps for Phase III with "Encouraging" Response Rates for NSCLC Immunotherapy

Retrieved on: 2021-06-24 17:48:45

Tags for this article:

Click the tags to see associated articles and topics

Arcus Preps for Phase III with "Encouraging" Response Rates for NSCLC Immunotherapy. View article details on HISWAI: https://www.biospace.com/article/arcus-preps-for-phase-iii-with-encouraging-response-rates-for-nsclc-immunotherapy

Excerpt

... co-develop and co-commercialize domvanalimab, an anti-TIGIT candidate and Fc-silent investigational monoclonal antibody. As Arcus continues to ...

Article found on: www.biospace.com

View Original Article

This article is found inside other Hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up